Entrada Therapeutics (TRDA) Free Cash Flow (2020 - 2026)
Entrada Therapeutics (TRDA) posted quarterly Free Cash Flow of -$41.7 million for Q1 2026, down 7.98% year-over-year from -$45.3 million in Q1 2025, and down 28.99% quarter-over-quarter from -$32.3 million in Q4 2025.
Powered by 
Analysis
Entrada Therapeutics (TRDA) Free Cash Flow (2020 - 2026) Analysis & Trends
Entrada Therapeutics' Free Cash Flow history runs 7 years deep, the most recent figure standing at -$41.7 million for Q1 2026.
- In Q1 2026, Free Cash Flow fell 7.98% year-over-year to -$41.7 million; the TTM figure through Mar 2026 stood at -$131.6 million (down 128.08% YoY), while the FY2025 annual figure was -$128.5 million, down 187.4% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$41.7 million, down from -$32.3 million in the prior quarter.
- The five-year high for Free Cash Flow was $194.8 million in Q1 2023, with the low at -$41.7 million in Q1 2026.
- The 5-year median for Free Cash Flow is -$27.3 million (2023), against an average of -$10.3 million.
- The sharpest annual moves came in 2023 and 2024: Free Cash Flow surged 1010.89% in 2023, then sank 637.76% in 2024.
- Entrada Therapeutics' Free Cash Flow stood at -$25.2 million in 2022, then soared by 80.21% to -$5.0 million in 2023, then tumbled by 637.76% to -$36.8 million in 2024, then advanced by 12.18% to -$32.3 million in 2025, then decreased by 28.99% to -$41.7 million in 2026.
- Business Quant data shows TRDA's Free Cash Flow at -$41.7 million in Q1 2026, -$32.3 million in Q4 2025, and -$28.3 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Entrada Therapeutics | 297.03 Mn | 297.03 Mn | - | -32.47 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -32.47 Mn |
| Mar 31, 2026 | -41.74 Mn |
| Dec 31, 2025 | -32.00 Mn |
| Sep 30, 2025 | -28.14 Mn |
| Jun 30, 2025 | -29.76 Mn |
| Mar 31, 2025 | -39.65 Mn |
| Dec 31, 2024 | -32.24 Mn |
| Sep 30, 2024 | -28.83 Mn |
| Jun 30, 2024 | 42.71 Mn |
| Mar 31, 2024 | -26.36 Mn |
| Dec 31, 2023 | -3.82 Mn |
| Sep 30, 2023 | -26.94 Mn |
| Jun 30, 2023 | -35.77 Mn |
| Mar 31, 2023 | 194.77 Mn |
| Dec 31, 2022 | -29.46 Mn |
| Sep 30, 2022 | -28.29 Mn |
| Jun 30, 2022 | -18.78 Mn |
| Mar 31, 2022 | -21.59 Mn |
| Dec 31, 2021 | -21.86 Mn |
| Sep 30, 2021 | -14.88 Mn |